In summary, results from these experiments reports a novel mechanistic role of DVL2 and HER2 depletion in modulating EGFR signaling activation in HER2+ breast cancer, which in turn, opens a new area of investigation of how Wnt and EGFR crosstalk might affect HER2+ breast cancer progression in the clinical setting. Here, DVL2 is linked to breast cancer.